Bellicum Pharmaceuticals Company Profile (NASDAQ:BLCM)

Bellicum Pharmaceuticals trades on the NASDAQ under the ticker symbol "BLCM."

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) posted its earnings results on Tuesday, August, 8th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.65) by $0.09. Bellicum Pharmaceuticals had a negative net margin of 17,957.31% and a negative return on equity of 70.74%. During the same period last year, the firm earned ($0.61) earnings per share. View Bellicum Pharmaceuticals' Earnings History.

Bellicum Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Bellicum Pharmaceuticals.

5 brokerages have issued 12-month price targets for Bellicum Pharmaceuticals' stock. Their forecasts range from $16.00 to $35.00. On average, they expect Bellicum Pharmaceuticals' stock price to reach $26.20 in the next year. View Analyst Ratings for Bellicum Pharmaceuticals.

Here are some recent quotes from research analysts about Bellicum Pharmaceuticals stock:

• 1. According to Zacks Investment Research, "Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. The Company's lead clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials. It is also developing BPX-201, a dendritic cell cancer vaccine, which is in a Phase I clinical trial for the treatment of metastatic castrate-resistant prostate cancer. Bellicum Pharmaceuticals, Inc. is based in Houston, Texas. " (3/16/2017)
• 2. Cantor Fitzgerald analysts commented, "Following Bellicum's 4Q16 earnings conference call, we are reiterating our Overweight rating and $32 price target. Bellicum provided several updates outlining its plans for 2017, including: 1) progress in its current BP-004 trial with BPX-501 in malignant and non-malignant pediatric transplant patients, 2) greater clarity from the FDA on the development path of BPX-501 in the U.S., and 3) updates on its expanding CAR and TCR oncology programs. Looking forward, we expect additional updated data at the European Hematology Association (EHA) meeting being held in June and an update on the finalized U.S. registration trial design in mid-2017." (3/14/2017)
• 3. Jefferies Group LLC analysts commented, "BLCM presented long term data consistent with the ASH 2016 readout, demonstrating low rates of GvHD and relapse. One theme of the meeting we found interesting was the ongoing debate on whether T cells are necessary to prevent BMT complications and relapse. Further, conversations with docs highlighted the discordant strategies for GvHD prevention." (2/27/2017)

Some companies that are related to Bellicum Pharmaceuticals include Alder BioPharmaceuticals (ALDR), G1 THERAPEUTICS (GTHX), AnaptysBio (ANAB), Ignyta (RXDX), Aclaris Therapeutics (ACRS), Paratek Pharmaceuticals (PRTK), Seres Therapeutics (MCRB), Achaogen (AKAO), CytomX Therapeutics (CTMX), Insys Therapeutics (INSY), Coherus BioSciences (CHRS), MacroGenics (MGNX), Adaptimmune Therapeutics PLC (ADAP), Synergy Pharmaceuticals (SGYP), Calithera Biosciences (CALA), Achillion Pharmaceuticals (ACHN), Sucampo Pharmaceuticals (SCMP) and Aurinia Pharmaceuticals (AUPH).

Bellicum Pharmaceuticals' management team includes the folowing people:

• James Farrell Brown, Independent Chairman of the Board
• Richard A. Fair, President, Chief Executive Officer, Director
• David M. Spencer Ph.D., Founder, Chief Scientific Officer
• Kevin M. Slawin M.D., Founder
• Alan A. Musso CPA, Chief Financial Officer, Treasurer
• Ken Moseley J.D., Senior Vice President, General Counsel, Corporate Secretary
• James M. Daly, Independent Director
• Stephen R. Davis, Independent Director
• Reid M. Huber Ph.D., Independent Director
• Frank B. McGuyer, Independent Director

(BLCM) raised $101 million in an initial public offering (IPO) on Thursday, December 18th 2014. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray served as the underwriters for the IPO and Trout Capital was co-manager.

Bellicum Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (8.43%), JPMorgan Chase & Co. (7.45%), Vanguard Group Inc. (3.64%), State Street Corp (1.25%), Northern Trust Corp (1.03%) and Sphera Funds Management LTD. (0.76%). Company insiders that own Bellicum Pharmaceuticals stock include Alan A Musso, Alan K Smith, Annemarie Moseley, Bros Advisors Lp Baker, David M Spencer, Ken Moseley, Kevin M Slawin and Thomas J Farrell. View Institutional Ownership Trends for Bellicum Pharmaceuticals.

Bellicum Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Kennedy Capital Management Inc., FMR LLC, Tudor Investment Corp ET AL, Mcdaniel Terry & Co., Fred Alger Management Inc. and Berson & Corrado Investment Advisors LLC. Company insiders that have sold Bellicum Pharmaceuticals stock in the last year include Alan A Musso, Alan K Smith, Annemarie Moseley, David M Spencer, Ken Moseley and Kevin M Slawin. View Insider Buying and Selling for Bellicum Pharmaceuticals.

Bellicum Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Vanguard Group Inc., Numeric Investors LLC, Goldman Sachs Group Inc., Northern Trust Corp, Virtu KCG Holdings LLC, State Street Corp and Sphera Funds Management LTD.. View Insider Buying and Selling for Bellicum Pharmaceuticals.

Shares of Bellicum Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Bellicum Pharmaceuticals stock can currently be purchased for approximately $11.41.